Incyte’s share price soars, driven by strong Q2 2025 results, Niktimvo’s impressive sales, and raised guidance for Jakafi. Find out why INCY stock is a buy.
Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio (NASDAQ:INCY)

16
Incyte’s share price soars, driven by strong Q2 2025 results, Niktimvo’s impressive sales, and raised guidance for Jakafi. Find out why INCY stock is a buy.